Transient expression of virus-like particles in plants: a promising platform for rapid vaccine production

Authors

  • Ebrahimi-Rad , M Biochemistry Department, Pasteur Institute of Iran, Pasteur Institute of Iran, Tehran, Iran.
  • Ehsani , P Molecular biology Department, Pasteur Institute of Iran, Pasteur Institute of Iran, Tehran, Iran.
  • Mohammadzadeh , S Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Ofoghi , H Department of Biotechnology , Iranian Research Organization of science and Technology, Tehran, Iran.
  • Rahimi , S Molecular biology Department, Pasteur Institute of Iran, Pasteur Institute of Iran, Tehran, Iran.
Abstract:

Transient expression is an efficient and fast system to express recombinant proteins which has been used in different eukaryotic hosts such as mammalian and plant cells. Several applications of this system have so far been used which expression of proteins of interest is one of them. Recently, plants have attracted attention for being used as hosts for the production of recombinant pharmaceutical proteins such as antibodies and vaccines due to their lower price of production, compared to the mammalian systems. Many studies have conducted on the rapid production of vaccine candidate proteins either as a monomer or virus-like particles during epidemics of fast-spreading diseases such as influenza. Virus-like particles have been expressed in prokaryotic and eukaryotic systems are demonstrated to be one of the best antigen presenting systems which can carry antigens in a safe repetitive format on a particle to induce immunity.. Here, we present recent advances in applying transient expression in plants that can be used to produce naked or enveloped virus-like particles as vaccine candidate as well some clinical trial studies.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Virus like particles as a platform for cancer vaccine development

Cancers have killed millions of people in human history and are still posing a serious health problem worldwide. Therefore, there is an urgent need for developing preventive and therapeutic cancer vaccines. Among various cancer vaccine development platforms, virus-like particles (VLPs) offer several advantages. VLPs are multimeric nanostructures with morphology resembling that of native viruses...

full text

Virus-like particles as vaccine.

This review presents data on commercial and experimental virus-like particle (VLP) vaccines, including description of VLP vaccines against influenza. Virus-like particles are multimeric, sometimes multiprotein nanostructures assembled from viral structural proteins and are devoid of any genetic material. VLPs present repetitive high-density displays of viral surface proteins. Importantly, they ...

full text

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from soluble recombinant antigens by stronger protective immunogenicity associated with the VLP structure. Like parental viruses, VLPs can be either non-enveloped or enveloped, and they can form following expression of one or several viral structural proteins in a recombinant heterologous system. Depending...

full text

Vaccine Potential of Nipah Virus-Like Particles

Nipah virus (NiV) was first recognized in 1998 in a zoonotic disease outbreak associated with highly lethal febrile encephalitis in humans and a predominantly respiratory disease in pigs. Periodic deadly outbreaks, documentation of person-to-person transmission, and the potential of this virus as an agent of agroterror reinforce the need for effective means of therapy and prevention. In this re...

full text

Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C

Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disease and liver transplantation. It poses a serious and growing worldwide public health problem that will only be partially addressed with the introduction of new antiviral therapies. However, these treatments will not prevent re-infection particularly in high risk populations. The introduction of a...

full text

Truncated Hepatitis B virus like nanoparticles: A novel drug delivery platform for cancer therapy

Nowadays, Nano-sized drug delivery systems have been studied extensively for theirpotential in cancer therapy. Various drug nanocarriers are being developed including liposomes, micelles, and Virus like nanoparticles (VLNPs). VLNPs offer many advantages for developing smart drug delivery systems due to their precise and repeated structures and relatively large cargo capacities. Truncated ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 3

pages  72- 80

publication date 2017-11

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023